“Glenmark’s profits crashed 86%—but the stock held strong. What’s the real story?”

📉 Financial Performance - Net Profit: ₹46.8 crore, down 86% YoY from ₹340.2 crore - Revenue from Operations: ₹3,264.4 crore, up 0.6% YoY - EBITDA: ₹580.4 crore, down 1% YoY from ₹588 crore - EBITDA Margin: 17.8%, slightly lower than 18.1% last year - Earnings Per Share: ₹1.66 (basic and diluted) 🌍 Segment-Wise Revenue - India: ₹1,239.9 crore, up 3.7% YoY, driven by cardiac, respiratory, and dermatology segments - North America: ₹778 crore, up 8.9% QoQ, supported by injectable and partnered product launches - Europe: ₹667.8 crore, down 4% YoY - Emerging Markets: ₹572.1 crore, flat YoY 💊 Product & Market Updates - Ryaltris (nasal spray): Commercialized in 45+ countries; expected launch in 10–12 more markets soon - QiNHAYO (oncology drug): Applications filed in ~15 markets; launch expected in FY26 - Winlevi (acne treatment): Approved in the UK; broader European rollout expected by end of FY26 📈 Major Support at Rs. 1900 📈 Major Resistance at Rs. 2100